Patients with chRCC RCC may benefit from mTOR inhibitors due to the mutation on chromosome 7 commonly described in these tumors, determining a loss of folliculin gene with upregulation of mTOR [31]. The gene discussed is FLCN; the disease is chromophobe renal cell carcinoma.